This page shows the latest ASP015K news and features for those working in and with pharma, biotech and healthcare.
Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3).
Heading the deal table is the $945m licence between Astellas Pharma and Janssen for the exclusive rights outside Japan to ASP015K, an oral janus kinase (JAK) inhibitor that is undergoing phase ... Astellas / Janssen. Licence. ASP015K for RA, psoriasis
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...